Liquidia Corporation  (LQDA)
Other Ticker:  
Price: $14.1300 $-0.46 -3.153%
Day's High: $14.505 Week Perf: -1.26 %
Day's Low: $ 12.80 30 Day Perf: 9.62 %
Volume (M): 1,256 52 Wk High: $ 15.15
Volume (M$): $ 17,747 52 Wk Avg: $8.14
Open: $14.50 52 Wk Low: $5.71

 Market Capitalization (Millions $) 916
 Shares Outstanding (Millions) 65
 Employees -
 Revenues (TTM) (Millions $) 18
 Net Income (TTM) (Millions $) -58
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 2

Liquidia Corporation
Liquidia Corporation is a pharmaceutical company that specializes in the development of therapeutics using its unique particle engineering technology. The company's proprietary PRINT technology allows for the precise engineering of particles to create drug candidates with improved performance and delivery. Liquidia focuses on developing both in-house and partnered therapeutics for various diseases, including respiratory diseases, cancer, and other conditions with significant unmet medical needs. The company aims to leverage its particle engineering capabilities to improve drug efficacy, safety, and patient outcomes.

   Company Address: 419 Davis Drive, Suite 100 Morrisville 27560 NC
   Company Phone Number: 328-4400   Stock Exchange / Ticker: NASDAQ LQDA
   LQDA is expected to report next financial results on March 19, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Liquidia Corporation Responds to United Therapeutics Lawsuit, Asserts Counterclaims and Highlights Patent Office Oversight Failure

Published Mon, Jan 8 2024 1:23 PM UTC

In a recent development in the pharmaceutical industry, Liquidia Corporation (NASDAQ: LQDA) has filed its response and counterclaims against United Therapeutics Corporation (UTHR). This legal battle revolves around alleged patent infringement regarding Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder. The filing also sheds light on several ...

Clinical Study

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Published Fri, Jan 5 2024 11:45 AM UTC

Liquidia Corporation, a leading pharmaceutical company, recently shared an update on the development of its extensive clinical pipeline programs aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension connected with interstitial lung disease (PH-ILD).The company's most promising investigational drugs, YUTREPIA (treprostinil) inhalation powder and L...

Financing Agreement

Liquidia Corporation Announces $100 Million in New Financings, Bolstering Financial Position and Advancing Growth Strategies

Published Thu, Jan 4 2024 2:11 PM UTC

Liquidia Corporation Secures $100 Million in New Capital, Enhancing Financial Position
MORRISVILLE, N.C., Jan. 04, 2024 - Liquidia Corporation (NASDAQ: LQDA), a cutting-edge biopharmaceutical company specializing in the development of therapeutics using its own innovative PRINT? technology, has recently announced two significant transactions that will inject an additiona...

Liquidia Corporation

Liquidia Corporation's Impressive Revenue Falls Short of Profitability in Fiscal Period Ending September 30, 2023

Liquidia Corporation, a renowned name in the industry, recently announced its financial results for the fiscal period ending September 30, 2023. As shareholders and stakeholders eagerly await these numbers, let's delve into the data to understand their implications and how they may shape the company's future trajectory.
Deficit Widens, but EPS Shows Encouraging Improvement:
Comparing the deficit per share from the previous year, Liquidia Corporation witnessed an increase from $-0.14 to $-0.24. Although this may raise concerns, the company managed to improve its earnings per share (EPS) from -$0.36 in the preceding quarter. This positive trend signals a potential recovery in the company's financial performance.

Liquidia Corporation

Liquidia Corporation Reports Impressive Revenue Surge, but Struggles to Achieve Profitability Amidst Increased Losses

Liquidia Corporation, a major player in the pharmaceutical preparations industry, recently announced a significant surge in revenue for the fiscal year ending June 30, 2023. The company reported a 22.154% increase in revenue, reaching $4.79 million compared to the previous year. This growth is particularly remarkable considering that most of Liquidia's peers in the industry experienced a decline in their top-line during the same period.
However, the news is not all positive for Liquidia Corporation. Despite the increase in revenue, the company also saw a significant increase in loss per share. It reported a loss of $0.36 per share, which is higher than the loss of $0.18 per share in the previous reporting period. This suggests that the company's expenses have outweighed its revenues, resulting in a larger net loss.


Liquidia's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com